Skip to main content

Advertisement

SpringerLink
Log in

The Role of Botox in Colorectal Disorders

  • Motility (H Parkman and R Schey, Section Editors)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of review

To overview the current medical literature on the efficacy of botulism toxin treatment (BTX-A) for lower gastrointestinal disorders (GIT).

Recent findings

BTX-A was found to have a short-term efficacy for the treatment of dyssynergic defecation. Surgical treatment was found to be more effective than BTX-A for the healing of chronic anal fissures, and BTX-A can be considered when surgery is undesirable. Data regarding the effects of BTX-A injection for the treatment of chronic anal pain is limited. Beneficial effects were observed only in a minority of patients. BTX-A treatment was found to be effective for the treatment of obstructive symptoms after surgery for Hirsprung’s disease as well as for the treatment of internal anal sphincter achalasia.

Summary

BTX-A treatment has a short-term efficacy and is safe. Further research is still needed in order to establish the exact place of BTX-A treatment of lower GIT disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Albanese A, Brisinda G, Mathias CJ. The autonomic nervous system and gastrointestinal disorders. In: Appenzeller O, Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology, vol. 75. Amsterdam: Amsterdam North-Holland Pub. Co; 2000. p. 613–63.

  2. •• Emile SH, Elfeki HA, Elbanna HG, et al. Efficacy and safety of botulinum toxin in treatment of anismus: a systematic review. World J Gastrointest Pharmacol Ther. 2016;7:453–62 This review provides a thorough evaluation of BTX-A in pelvic dyssynergia.

    Article  Google Scholar 

  3. Brisinda G, Sivestrini N, Bianco G, Maria G. Treatment of gastrointestinal sphincters spasms with botulinum toxin A. Toxins. 2015;7:1882–916.

    Article  CAS  Google Scholar 

  4. Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterol Motil. 2006;18:507–19.

    Article  CAS  Google Scholar 

  5. Rao SS, Tuteja AK, Vellema T, et al. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol. 2004;38:680–5.

    Article  Google Scholar 

  6. Kuijpers HC, Bleijenberg G. The spastic pelvic floor syndrome. A cause of constipation. Dis Colon Rectum. 1985;28:669–72.

    Article  CAS  Google Scholar 

  7. Andromanakos N, Skandalakis P, Troupis T, Filippou D. Constipation of anorectal outlet obstruction: pathophysiology, evaluation and management. J Gastroenterol Hepatol. 2006;21:638–46.

    Article  Google Scholar 

  8. Patcharatrakul T, Rao SSC. Update on the pathophysiology and management of anorectal disorders. Gut Liver. 2018;12:375–84.

    Article  Google Scholar 

  9. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–94.

    Article  CAS  Google Scholar 

  10. Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum a toxin. Lancet. 1988;2:714–7.

    Article  CAS  Google Scholar 

  11. Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD. Initial north American experience with botulinum toxin type a for treatment of anismus. Dis Colon Rectum. 1996;39:1107–11.

    Article  CAS  Google Scholar 

  12. Shafik A, El-Sibai O. Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg. 1998;15:347–51.

    Article  CAS  Google Scholar 

  13. Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum. 2001;44:1821–6.

    Article  CAS  Google Scholar 

  14. Farid M, El Monem HA, Omar W, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Color Dis. 2009;24:115–20.

    Article  Google Scholar 

  15. Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type a botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006;101:2570–5.

    Article  Google Scholar 

  16. Zhang Y, Wang ZN, He L, Gao G, Zhai Q, Yin ZT, et al. Botulinum toxin type-a injection to treat patients with intractable anismus unresponsive to simple biofeedback training. World J Gastroenterol. 2014;20:12602–7.

    Article  CAS  Google Scholar 

  17. Farid M, Youssef T, Mahdy T, Omar W, Moneim HA, El_Nakeeb A, et al. Comparative study between botulinum toxin injection and partial division of puborectalis for treating anismus. Int J Color Dis. 2009;24:327–34.

    Article  Google Scholar 

  18. Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997–1003.

    Article  CAS  Google Scholar 

  19. Hompes R, Harmston C, Wijffels N, Jones OM, Cunningham C, Lindsey I. Excellent response rate of anismus to botulinum toxin if rectal prolapse misdiagnosed as anismus (‘pseudoanismus’) is excluded. Color Dis. 2012;14:224–30.

    Article  CAS  Google Scholar 

  20. Whitehead WE, Wald A, Diamant NE, et al. Functional disorders of the anus and rectum. Gut. 1999;45:1155–9.

    Google Scholar 

  21. Grimaud JC, Bouvier M, Naudy B, Guien C, Salducci J. Manometric and radiologic investigations and biofeedback treatment of chronic idiopathic anal pain. Dis Colon Rectum. 1991;34:690–5.

    Article  CAS  Google Scholar 

  22. Jeyarajah S, Chow A, Ziprin P, et al. Proctalgia fugax, an evidence-based management pathway. Int J Color Dis. 2010;9:1037–46.

    Article  Google Scholar 

  23. Atkin GK, Suliman A, Vaizey CJ. Patient characteristics and treatment outcome in functional anorectal pain. Dis Colon Rectum. 2011;54:870–5.

    Article  Google Scholar 

  24. Christiansen J, Bruun E, Skjoldbye B, Hagen K. Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum. 2001;44:661–5.

    Article  CAS  Google Scholar 

  25. Hollingshead JR, Maeda Y, Brown TJ, et al. Long-term outcome of the use of botulinum toxin injection for functional anal pain. Color Dis. 2011;13:293–6.

    Article  Google Scholar 

  26. •• Mapel DW, Schum M, Von Worley A. The epidemiology and treatment of anal fissures in a population-based cohort. BMC Gastroenterol. 2014;14:129 This review provides a thorough evaluation of different treatments for anal fissures and the role of BTX-A.

    Article  Google Scholar 

  27. Lindsey I, Jones OM, Cunningham C, Mortensen NJMC. Chronic anal fissure. Br J Surg. 2004;91:270–9.

    Article  CAS  Google Scholar 

  28. Herzig DO, Lu KC. Anal fissure. Surg Clin North Am. 2010;90:33–44.

    Article  Google Scholar 

  29. Griffin N, Acheson AG, Tung P, Sheard C, Glazebrook C, Scholefield JH. Quality of life in patients with chronic anal fissure. Color Dis. 2004;6:39–44.

    Article  CAS  Google Scholar 

  30. Liratzopoulos N, Efremidou EI, Papageorgiou MS, Kouklakis G, Moschos J, Manolas KJ, et al. Lateral subcutaneous internal sphincterotomy in the treatment of chronic anal fissure: our experience. J Gastrointestin Liver Dis. 2006;15(2):143–7.

    PubMed  Google Scholar 

  31. Garg P, Garg M, Menon GR. Long-term continence disturbance after lateral internal sphincterotomy for chronic anal fissure: a systematic review and meta-analysis. Color Dis. 2013;15:104–17.

    Article  Google Scholar 

  32. Chen HL, Woo XB, Wang HS, Lin YJ, Luo HX, Chen YH, et al. Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta-analysis of randomized control trials. Tech Coloproctol. 2014;18:693–8.

    Article  Google Scholar 

  33. Altomare DF, Rinaldi M, Milito G, Arcana F, et al. Glyceryl trinitrate for chronic anal fissure—healing or headache? Results of a multicenter, randomized, placebo-controlled double blind trial. Dis Colon Rectum. 2000;43:174–9.

    Article  CAS  Google Scholar 

  34. Antripoli C, Perrotti P, Rubino M, Martino A, et al. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum. 1999;42:1011–5.

    Article  Google Scholar 

  35. Bielecki K, Kolodziejczak M. A prospective randomized trial of diltiazem and glyceryltrinitrate ointment in the treatment of chronic anal fissure. Color Dis. 2003;5:256–7.

    Article  CAS  Google Scholar 

  36. Jensen SL. Treatment of first episodes of acute anal fissure: a prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. Br Med J. 1986;292:1167–70.

    Article  CAS  Google Scholar 

  37. Eshghi F. The efficacy of L-arginine gel for treatment of chronic anal fissure compared to surgical sphincterotomy. J Med Sci. 2007;7:481–4.

    Article  CAS  Google Scholar 

  38. Gaj F, Trecca A, Crispino P. Efficacy of anal dilators in the treatment of acute anal fissure. A controlled clinical trial. Chir Ital. 2006;58:761–5.

    PubMed  Google Scholar 

  39. Gupta P. Randomized, controlled study comparing sitzbath and no-sitz-bath treatments in patients with acute anal fissures. ANZ J Surg. 2006;76:718–21.

    Article  Google Scholar 

  40. Jensen SL. Maintenance therapy with unprocessed bran in the prevention of acute anal fissure recurrence. J R Soc Med. 1987;80:296–8.

    Article  CAS  Google Scholar 

  41. Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am J Surg. 2000;179:46–50.

    Article  CAS  Google Scholar 

  42. Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery. 2002;131:179–84.

    Article  Google Scholar 

  43. Nelson RL, Thomas K, Morgan J, et al. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012;15(2):CD00343.

    Google Scholar 

  44. Sahebally SM, Meshkat B, Walsh SR, Beddy D. Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials. Color Dis. 2018;20:6–15.

    Article  CAS  Google Scholar 

  45. Arroyo A, Perez F, Serrano P, et al. Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study. Am J Surg. 2005;189:429–34.

    Article  CAS  Google Scholar 

  46. Minguez M, Herreros B, Espi A, et al. Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology. 2002;123:112–7.

    Article  Google Scholar 

  47. Mentes BB, Irkorucu O, Akin, et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum. 2003;46:232–7.

    Article  Google Scholar 

  48. Davies J, Duffy D, Boyt N, Aghahoseini A, Alexander D, Leveson S. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum. 2003;46:1097–102.

    Article  Google Scholar 

  49. Chumpitazi BP, Nurko S. Defecation disorders in children after surgery for Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2011;53:75–9.

    Article  Google Scholar 

  50. Langer JC. Persistent obstructive symptoms after surgery for Hirschsprung’s disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg. 2004;39:1458–62.

    Article  Google Scholar 

  51. Neilson IR, Yazbeck S. Ultrashort Hirschsprung’s disease: myth or reality. J Pediatr Surg. 1990;25:1135–8.

    Article  CAS  Google Scholar 

  52. Minkes RK, Langer JC. A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung’s disease. J Pediatr Surg. 2000;35:1733–6.

    Article  CAS  Google Scholar 

  53. Han-Geurts IJ, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric botox injection in children with surgically treated Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2014;59:604–7.

    Article  CAS  Google Scholar 

  54. Friedmacher F, Puri P. Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis. Pediatr Surg Int. 2012;28:765–71.

    Article  Google Scholar 

  55. •• Church JT, Gadepalli SK, Talishinsky T, et al. Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung’s disease and internal anal sphincter achalasia. J Pediatr Surg. 2017;52:74–8 This study examines the efficacy of a targeted BTX-A treatment in Hirschsprung’s disease and internal anal sphincter achalasia.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Derech Sheba 2, Ramat Gan, Israel

    Dan Carter MD

  2. Sackler Faculty of Medicine, Tel Aviv University, P.O.B 39040, 69978, Ramat Aviv, Israel

    Dan Carter MD & Ram Dickman MD

  3. Division of Gastroenterology, Rabin Medical Center, Ze’ev Jabotinsky St 39, 4941492, Petah Tikva, Israel

    Ram Dickman MD

Authors
  1. Dan Carter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ram Dickman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ram Dickman MD.

Ethics declarations

Conflict of Interest

Dan Carter reports personal fees from Takeda, Abbvie, and Janssen, outside the submitted work. Ram Dickman declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Motility

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carter, D., Dickman, R. The Role of Botox in Colorectal Disorders. Curr Treat Options Gastro 16, 541–547 (2018). https://doi.org/10.1007/s11938-018-0205-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-018-0205-z

Keywords

Search

Navigation